Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.45 |
| ▸ | CTSD | P07339 | 3/20 | 0.43 |
| ▸ | CTSE | P14091 | 3/20 | 0.43 |
| ▸ | BACE1 | P56817 | 3/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.41 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18619693 | 1.00 | MALT1 (0.56) | MALT1OPRM1OPRK1CTSDCTSE | |
| SCHEMBL18619638 | 0.91 | MALT1 (0.57) | MALT1OPRM1OPRK1RENNMUR2 | |
| SCHEMBL22209395 | 0.90 | MALT1 (0.52) | MALT1OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL18619604 | 0.90 | MALT1 (0.52) | MALT1OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL18619694 | 0.88 | MALT1 (0.65) | MALT1OPRM1OPRK1CTSDCTSE | |
| SCHEMBL18620806 | 0.88 | MALT1 (0.65) | MALT1OPRM1OPRK1CTSDCTSE | |
| SCHEMBL22209365 | 0.86 | MALT1 (0.64) | MALT1CMA1 | |
| SCHEMBL22811073 | 0.86 | MALT1 (0.64) | MALT1CMA1 | |
| SCHEMBL18621052 | 0.86 | MALT1 (0.64) | MALT1CMA1 | |
| SCHEMBL18619572 | 0.86 | MALT1 (0.64) | MALT1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10711036-B2 | MALT1 inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2017040304-A1 | MALT1 INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711036-B2 | MALT1 inhibitors and uses thereof | MALT1, BCL3, BCL6 | MALT1 1/4885OPRM1 4525/4885OPRK1 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.